Table 6.
Clinical and demographic characteristics of NMOSD patients at the date of the 1st dose of COVID-19 vaccine or COVID-9 onset.
| Vaccinated | Post-COVID-19 | |
|---|---|---|
| Study population | 17 | 8 |
| Age, mean (SD), y | 49.09 (14.50) | 53.33 (10.27) |
| <55 | 11 (64.71%) | 6 (75.00%) |
| >=55 | 6 (35.29%) | 2 (25.00%) |
| Female | 16 (94.12%) | 5 (62.50%) |
| NMOSD duration (SD), y | 17.17 (11.26) | 10.66 (5.04) |
| EDSS | ||
| EDSS < 4 | 7 (41.18%) | 6 (75.00%) |
| EDSS >= 4 | 10 (58.82%) | 2 (25.00%) |
| DMT | 15 (88.24%) | 5 (62.50%) |
| Rituximab | 13 (76.47%) | 5 (62.50%) |
| Inebilizumab | 2 (11.76%) | 0 |
| No DMT | 2 (11.76%) | 3 (37.50%) |
| COVID-19 vaccine | ||
| BNT162b2 (Comirnaty) – mRNA | 17 (100%) | |
| Time between doses (SD), d | 28.82 (7.84) | |
| COVID-19 severity | ||
| Death | 2 (25%) | |
| Need of invasive ventilation or extracorporeal membrane oxygenation | 0 | |
| Need of non-invasive ventilation or high-flow oxygen therapy | 0 | |
| Need of supplemental oxygen | 0 | |
| Radiologically confirmed pneumonia | 2 (25%) | |
| Suspected pneumonia (dry cough, fever and shortness of breath) | 0 | |
| Symptomatic | 4 (50%) | |
| Asymptomatic | 0 | |
| Patients with at least 1 clinical relapse | ||
| In 90 days after vaccination | 1 (5.88%) | |
| Time between 1st dose of vaccine and relapse (SD), d | 41 | |
| Between 0–90 days before vaccination | 0 | |
| Between 90–180 days before vaccination | 0 | |
| Between 180–270 days before vaccination | 0 | |
| Between 360–270 days before vaccination | 2 (11.76%) | |
| In 90 days after COVID-19 | 2 (25%) | |
| Time between COVID-19 onset and acute relapse (SD), d | 30 (7.07) | |
| Between 0–90 days before COVID-19 | 0 | |
| Between 90–180 days before COVID-19 | 0 | |
| Between 180–270 days before COVID-19 | 1 (12.5%) | |
| Between 270–360 days before COVID-19 | 1 (12.5%) |
NMOSD = neuromyelitis optica spectrum disorder; EDSS = expanded disability status scale; DMT = disease modifying treatment.